Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Critical Care
Volume 2017, Article ID 3818407, 5 pages
Case Report

Use of Hemadsorption in a Case of Pediatric Toxic Shock Syndrome

1Department of Pediatrics, University of Debrecen, Debrecen 4012, Hungary
2Institute of Laboratory Medicine, University of Debrecen, Debrecen 4012, Hungary
3Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen 4012, Hungary
4Fresenius Medical Care, NephroCare University of Debrecen, Debrecen 4012, Hungary
5HAS-UD Vascular Biology and Myocardial Pathophysiology Research Group, Hungarian Academy of Sciences, Debrecen 4012, Hungary

Correspondence should be addressed to József Balla; moc.akinilkleb@allab

Received 10 May 2017; Accepted 14 June 2017; Published 16 July 2017

Academic Editor: Mehmet Doganay

Copyright © 2017 Andrea Berkes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Toxic shock syndrome is a potentially fatal toxin-mediated disease. The role of toxins in this clinical entity made us hypothesize that extracorporeal blood purification with CytoSorb® could play a beneficial role in the clinical management of toxic shock syndrome. This case report describes the successful treatment of toxic shock syndrome using a combination of renal replacement therapy and hemadsorption in a pediatric patient. Case Presentation. A 5-year-old girl with Down’s syndrome presented with an inflamed area surrounding an insect bite, signs of systemic inflammation, and multiple organ failure. As previous attempts of immune modulation therapy were unsuccessful, renal replacement therapy was supplemented by the cytokine absorber CytoSorb. Treatment using this combination was associated with a rapid and significant stabilization in the hemodynamic situation and a decrease in inflammatory mediators within hours after the initiation of therapy. The application of CytoSorb therapy was simple and safe. Conclusion. The use of extracorporeal blood purification with CytoSorb proved potentially beneficial by removing toxins and inflammatory mediators in this case and could therefore play a role in the clinical management of toxic shock syndrome. Whether CytoSorb has the potential to even positively influence mortality in patients with toxic shock syndrome still needs to be confirmed.